Jiangsu Kanion PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 4/4

Jiangsu Kanion PharmaceuticalLtd CEO'su Yongchun Yang, Apr2021 tarihinde atandı, in görev süresi 3.58 yıldır. şirketin hisselerinin 0.037% doğrudan sahiptir ve bu hisselerin değeri CN¥ 3.00M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 3.5 yıldır.

Anahtar bilgiler

Yongchun Yang

İcra Kurulu Başkanı

CN¥758.6k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.6yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yongchun Yang (51 yo)

3.6yrs

Görev süresi

CN¥758,600

Tazminat

Mr. Yongchun Yang is General Manager at Jiangsu Kanion Pharmaceutical Co. Ltd. since April 9, 2021 and has been its Director since December 27, 2019. Mr. Yang served as Chief Marketing Officer and Deputy G...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yongchun Yang	GM & Director	3.6yrs	CN¥758.60k	0.037% CN¥ 3.0m
Suocheng Jiang	Deputy Chief Accountant	1.8yrs	CN¥207.50k	0.0044% CN¥ 357.2k
Feipeng Xian	Deputy General Manager	1.4yrs	CN¥521.10k	0.0070% CN¥ 571.3k
Quan Liu	Deputy General Manager	4.9yrs	CN¥742.70k	0.025% CN¥ 2.0m
Yu Pan	Deputy GM & Market Development Center	2.7yrs	CN¥1.07m	0.025% CN¥ 2.0m
Yun Wu	Deputy General Manager	1.4yrs	CN¥637.00k	0.018% CN¥ 1.5m
Chuanlei Wang	Deputy General Manager	2.7yrs	CN¥710.40k	0.025% CN¥ 2.0m
Pan Peng	Secretary	less than a year	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

47.5yo

Ortalama Yaş

Deneyimli Yönetim: 600557 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yongchun Yang	GM & Director	4.9yrs	CN¥758.60k	0.037% CN¥ 3.0m
Wei Xiao	Chairman	24yrs	CN¥2.39m	2.99% CN¥ 243.0m
Zhenzhong Wang	Vice Chairman of the Board	8.2yrs	CN¥1.03m	0.037% CN¥ 3.0m
Meiling Jiang	Supervisor	1.4yrs	Veri yok	Veri yok
Min Xu	Independent Director	3.5yrs	CN¥100.00k	Veri yok
Kaixian Chen	Independent Director	4.9yrs	CN¥100.00k	Veri yok
Wu Di	Supervisor	2.5yrs	Veri yok	Veri yok
Xuebin Chen	Director	1.4yrs	CN¥641.10k	0.0098% CN¥ 799.9k
Lin Jiang	Supervisor	1.4yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600557 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Jiangsu Kanion PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Earnings quality

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) agreed to acquire Jiangsu Zhongxin Medicine Co.,Ltd. from Jiangsu Kanion Group Co Ltd and Nanjing Kangzhu Enterprise Management Partnership (Limited Partnership) for CNY 270 million.

Investor sentiment improves as stock rises 15%

Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 2Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Jul 27, 2024

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.25 in 1Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Investor sentiment improves as stock rises 18%

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Full year 2023 earnings released: EPS: CN¥0.93 (vs CN¥0.75 in FY 2022)

Now 20% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) announces an Equity Buyback for CNY 150 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 11, 2024

New minor risk - Share price stability

Now 20% undervalued

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 2Q 2022)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Jul 13, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.75 (vs CN¥0.56 in FY 2021)

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.081 in 3Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.86 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥9.43

New 90-day low: CN¥10.99

New 90-day low: CN¥12.14

Third quarter earnings released

New 90-day low: CN¥12.29

New 90-day low - CN¥12.67

New 90-day low - CN¥12.93

First half earnings released

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş